Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

A defined subunit vaccine that protects against vector-borne visceral leishmaniasis.

Duthie MS, Pereira L, Favila M, Hofmeyer KA, Reed SJ, Metangmo S, Townsend S, Laurance JD, Picone A, Misquith A, Hossain F, Ghosh P, Khan MAA, Guderian J, Bailor HR, Liang H, Vergara J, Oliveira F, Howard RF, Kamhawi S, Mondal D, Coler RN, Valenzuela JG, Reed SG.

NPJ Vaccines. 2017 Aug 21;2:23. doi: 10.1038/s41541-017-0025-5. eCollection 2017.

2.

IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.

Desbien AL, Dubois Cauwelaert N, Reed SJ, Bailor HR, Liang H, Carter D, Duthie MS, Fox CB, Reed SG, Orr MT.

J Immunol. 2016 Dec 1;197(11):4351-4359. Epub 2016 Oct 28.

3.

Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis.

Duthie MS, Favila M, Hofmeyer KA, Tutterrow YL, Reed SJ, Laurance JD, Picone A, Guderian J, Bailor HR, Vallur AC, Liang H, Mohamath R, Vergara J, Howard RF, Coler RN, Reed SG.

Vaccine. 2016 May 27;34(25):2779-86. doi: 10.1016/j.vaccine.2016.04.067. Epub 2016 May 1.

4.

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.

Coler RN, Duthie MS, Hofmeyer KA, Guderian J, Jayashankar L, Vergara J, Rolf T, Misquith A, Laurance JD, Raman VS, Bailor HR, Cauwelaert ND, Reed SJ, Vallur A, Favila M, Orr MT, Ashman J, Ghosh P, Mondal D, Reed SG.

Clin Transl Immunology. 2015 Apr 10;4(4):e35. doi: 10.1038/cti.2015.6. eCollection 2015 Apr.

5.

Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ.

Desbien AL, Reed SJ, Bailor HR, Dubois Cauwelaert N, Laurance JD, Orr MT, Fox CB, Carter D, Reed SG, Duthie MS.

Eur J Immunol. 2015 Feb;45(2):407-17. doi: 10.1002/eji.201444543. Epub 2014 Dec 3.

6.

Development and pre-clinical assessment of a 73 kD chimeric fusion protein as a defined sub-unit vaccine for leprosy.

Duthie MS, Sampaio LH, Oliveira RM, Raman VS, O'Donnell J, Bailor HR, Ireton GC, Sousa AL, Stefani MM, Reed SG.

Vaccine. 2013 Jan 21;31(5):813-9. doi: 10.1016/j.vaccine.2012.11.073. Epub 2012 Dec 8.

PMID:
23228811
7.

Targeting TLRs expands the antibody repertoire in response to a malaria vaccine.

Wiley SR, Raman VS, Desbien A, Bailor HR, Bhardwaj R, Shakri AR, Reed SG, Chitnis CE, Carter D.

Sci Transl Med. 2011 Jul 27;3(93):93ra69. doi: 10.1126/scitranslmed.3002135.

8.

Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis.

Raman VS, Bhatia A, Picone A, Whittle J, Bailor HR, O'Donnell J, Pattabhi S, Guderian JA, Mohamath R, Duthie MS, Reed SG.

J Immunol. 2010 Aug 1;185(3):1701-10. doi: 10.4049/jimmunol.1000238. Epub 2010 Jul 2.

9.

Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection.

Raman VS, O'Donnell J, Bailor HR, Goto W, Lahiri R, Gillis TP, Reed SG, Duthie MS.

Infect Immun. 2009 Dec;77(12):5623-30. doi: 10.1128/IAI.00508-09. Epub 2009 Sep 28.

Supplemental Content

Loading ...
Support Center